Key points are not available for this paper at this time.
Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems.
Share your take
Add a clinician perspective alongside expert commentary.
Nadkarni et al. (2017) studied this question.